ArticleHemaSphere2019

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients.

Bianca R Schnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.